The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.
Pegasys and Copegus Indications Expanded to Include Treatment of Hepatitis C and HIV Coinfection
FDA approved, on February 25, 2005, efficacy supplements for Pegasys (peginterferon alfa-2a) and Copegus (ribavirin), making them the first approved therapies for treatment of Hepatitis C in patients coinfected with HIV. The approvals expand the therapeutic indications to include Peginteferon alone, or in combination with ribavirn, for the treatment of adult chronic hepatitis C in patients coinfected with HIV, who have clinically stable HIV disease (patients either on stable HIV antiretroviral therapy, or those who have not met the criteria to begin therapy).
Note that patients receiving Pegasys/Copegus and Nucleoside Reverse Transcriptase Inhibitors (NRTIs) should be closely monitored for treatment-associated toxicities.
Descriptive information about the clinical trial to support the supplement are contained in respective product labeling. (See Study 6.)
Pegasys and Copegus are manufactured by Hoffmann-La Roche Inc., Nutley, NJ
HIV/AIDS Program Director
Office of Special Health Issues
Food and Drug Administration